Time differentiation for intravitreal treatments (IVT)between ranibizumab (Lucentis)vial and ranibizumab (Lucentis) pre-filled syringe (PFS) in real life clinical practice

Trial Profile

Time differentiation for intravitreal treatments (IVT)between ranibizumab (Lucentis)vial and ranibizumab (Lucentis) pre-filled syringe (PFS) in real life clinical practice

Completed
Phase of Trial: Phase IV

Latest Information Update: 17 Jun 2016

At a glance

  • Drugs Ranibizumab (Primary)
  • Indications Age-related macular degeneration; Choroidal neovascularisation; Degenerative myopia; Diabetic macular oedema; Diabetic retinopathy; Retinal oedema
  • Focus Therapeutic Use
  • Sponsors Novartis
  • Most Recent Events

    • 12 May 2016 Status changed from active, no longer recruiting to completed.
    • 05 Feb 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top